Grants and Contracts Details
Description
Group B Streptococcus (GBS) is a normal constituent of the intestinal and vaginal flora
in 15–30% of healthy adults. The bacterium can, however, cause infections in elderly and
immunocompromised patients, pregnant women, and is the main case of fatal invasive disease
in newborns. For the development of sepsis and meningitis, GBS colonizes the colon and the
small intestine, translocates across the intestinal epithelium, spreads in the bloodstream,
evades immune mechanisms preventing GBS clearance from the blood stream and finally
disrupts the blood-brain barrier entering the central nervous system. A key virulence factor, a
GBS pore-forming toxin β-hemolysin (also known as the β-hemolytic lipid pigment or
granadaene) facilitates translocation across the epithelial and endothelial walls, including the
blood–brain barrier. The genes responsible for the hemolytic pigment expression are encoded in
the cyl gene cluster which is negatively regulated by the major two-component system CovS/R
and the redox-sensing regulator Rex. Because many haemolytic strains of GBS are not
pigmented on blood agar, detection of GBS pigment is generally carried out on the starch-serum
based Granada-type media in which the production of the toxin is stimulated by a folate pathway
inhibitor. We developed a new chemically defined medium (CDM) which triggers the pigment
expression. Using this medium, we demonstrated that the unknown molecule secreted by GBS
strains strongly inhibits the production of β-hemolysin. Here we propose to use the new CDM to
screen the transposon library of GBS CJB111 to identify the mechanisms of regulation of β-
hemolysin expression. Using RNA-seq approach, we additionally identify GBS genes
dysregulated by the inhibitor molecule. Isogenic mutants in the candidate genes defined by
transposon and RNA-seq approaches will be constructed and analyzed to determine if gene
deletions affect β-hemolysin expression and regulation of the cyl gene cluster. The results of
this exploratory work have a potential to lead to development of a novel drug which inhibits the
invasion state of GBS.
Status | Active |
---|---|
Effective start/end date | 5/19/23 → 4/30/25 |
Funding
- National Institute of Allergy and Infectious Diseases: $420,750.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.